Gyroscope Therapeutics GTSCOPE
Posted by: Georgia Retina in
Research Title: A Study of Disease Progression in Genetically Defined Subjects with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) Sponsor: Gyroscope Therapeutics Principal Investigator: Robert A. Stoltz, M.D., Ph.D. Description: Prospective, observational study to evaluate the natural progression of anatomical and functional visual parameters in genetically defined subjects with GA due to AMD. Start Date: March 2019 Recruitment: Enrolling…
Read More
Iveric Bio ISEE2008 GATHER2
Posted by: Georgia Retina in
Research Title: A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Sponsor: IVERIC bio, Inc. Principal Investigator: Atul Sharma, MD Description: The objectives of this study are to evaluate the safety and efficacy…
Read More Novartis CRTH258A2303 TALON
Posted by: Georgia Retina in
Research Title: A 64-week, Two-arm, Randomized, Double-masked, Multicenter, Phase IIIb Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen in Patients with Neovascular Agerelated Macular Degeneration (TALON) Sponsor: Novartis Pharmaceuticals Principal Investigator: Robert Stoltz, M.D., Ph.D. Description: The study is a 64-week randomized, double-masked, multi-center, active-controlled, two-arm study in…
Read More Amgen 20170542
Posted by: Georgia Retina in
Research Title: A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects With Neovascular Age-related Macular Degeneration Sponsor: Amgen Principal Investigator: Atul Sharma, MD Description: The purpose of this study is to compare the efficacy and safety of ABP 938 versus Aflibercept (Eylea®) in the treatment of neovascular age-related macular degeneration….
Read More Apellis APL2-303 DERBY
Posted by: Georgia Retina in
Research Title: A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) Sponsor: Apellis Pharmaceuticals, Inc. Principal Investigator: Robert Stoltz, M.D., Ph.D. Description: This is a 30-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to…
Read More Gemini GEM-NH-001 Clarity 1
Posted by: Georgia Retina in
Research Title: A Genetic Screening and Registry Study to Evaluate Long-term Clinical Outcomes and Disease Progression in Subjects with Non-Central Geographic Atrophy (GA) Who are Carriers of High-Risk Genetic Complement Variants Associated with Dry Age-related Macular Degeneration (AMD) Sponsor: Gemini Therapeutics, Inc. Principal Investigator: Robert Stoltz, M.D., Ph.D. Description: This is a prospective, multicenter, longitudinal registry, conducted in subjects…
Read More Genentech GR40349 YOSEMITE
Posted by: Georgia Retina in
Research Title: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients With Diabetic Macular Edema (YOSEMITE). Sponsor: Genentech, Inc. / Hoffmann-La Roche Principal Investigator: Robert A. Stoltz, M.D., Ph.D. Description: This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in…
Read More Genentech GR40548 ARCHWAY
Posted by: Georgia Retina in
Research Title: Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration Sponsor: Genentech, Inc. / Hoffmann-La Roche Principal Investigator: Robert A. Stoltz, M.D., Ph.D. Description: Study GR40548 is a Phase III, randomized, multicenter, open-label (visual assessor [VA]-masked), active-comparator study designed…
Read More Genentech GR40973 Gallego
Posted by: Georgia Retina in
Research Title: A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GALLEGO) Sponsor: Genentech, Inc. Principal Investigator: Robert Stoltz, M.D., Ph.D. Description: This study will evaluate the safety, tolerability, and efficacy of intravitreal injections of RO7171009 administered every 4…
Read More NGM Biopharmaceuticals NGM621-GA-201 CATALINA
Posted by: Georgia Retina in
Research Title: A Phase 2 Multicenter, Randomized, Double-Masked, Sham-Controlled Study of the Safety and Efficacy of Intravitreal Injections of NGM621 in Subjects With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) Sponsor: NGM Biopharmaceuticals, Inc. Principal Investigator: Robert A. Stoltz, MD, PhD Description: This is a multi-center evaluation of NGM621 in a randomized, double-masked, sham-controlled study in participants…
Read More 
